Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 5/2013

01.10.2013 | Review

Circulating nucleic acids as biomarkers in breast cancer

verfasst von: Heidi Schwarzenbach

Erschienen in: Breast Cancer Research | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

During tumor development, tumor cells release their nucleic acids into the blood circulation. This process occurs by apoptotic and necrotic cell deaths along with active cell secretion, resulting in high levels of circulating DNA, mRNA, and microRNA in the blood of patients with breast cancer. As circulating cell-free tumor nucleic acids may reflect the characteristics of the primary tumor and even of micrometastatic cells, they may be excellent blood biomarkers for screening breast cancer. Assays that allow the repetitive monitoring of patients by using blood samples as liquid biopsy may be efficient in assessing cancer progression in patients whose tumor tissue is not available. This review evaluates the recent data on the potential use of circulating cell-free nucleic acids as biomarkers for breast cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Mandel P, Métais P: Nucleic acids in human blood plasma. C R Acad Sci Paris. 1948, 142: 241-243. Article in French
2.
Leon SA, Shapiro B, Sklaroff DM, Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37: 646-650.PubMed
3.
Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989, 46: 318-322. 10.1159/000226740.PubMedCrossRef
4.
Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL: Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994, 3: 67-71.PubMed
5.
Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M: Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994, 86: 774-779. 10.1111/j.1365-2141.1994.tb04828.x.PubMedCrossRef
6.
Schwarzenbach H, Hoon DS, Pantel K: Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer. 2011, 11: 426-437. 10.1038/nrc3066.PubMedCrossRef
7.
Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, Anker P: Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res. 2000, 6: 3823-3826.PubMed
8.
Zhu W, Qin W, Atasoy U, Sauter ER: Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009, 2: 89-10.1186/1756-0500-2-89.PubMedPubMedCentralCrossRef
9.
Schwarzenbach H, Alix-Panabieres C, Muller I, Letang N, Vendrell JP, Rebillard X, Pantel K: Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res. 2009, 15: 1032-1038. 10.1158/1078-0432.CCR-08-1910.PubMedCrossRef
10.
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R: DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 2001, 61: 1659-1665.PubMed
11.
Stroun M, Lyautey J, Lederrey C, Olson-Sand A, Anker P: About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta. 2001, 313: 139-142. 10.1016/S0009-8981(01)00665-9.PubMedCrossRef
12.
Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, Diaz LA, Goodman SN, David KA, Juhl H, Kinzler KW, Vogelstein B: Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci USA. 2005, 102: 16368-16373. 10.1073/pnas.0507904102.PubMedPubMedCentralCrossRef
13.
Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananév V, Bazin I, Garin A, Narimanov M, Knysh V, Melkonyan H, Umansky S, Lichtenstein A: Genetic analysis of DNA excreted in urine: a new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem. 2000, 46 (8 Pt 1): 1078-1084.PubMed
14.
Minchin RF, Carpenter D, Orr RJ: Polyinosinic acid and polycationic liposomes attenuate the hepatic clearance of circulating plasmid DNA. J Pharmacol Exp Ther. 2001, 296: 1006-1012.PubMed
15.
Fleischhacker M, Schmidt B: Circulating nucleic acids (CNAs) and cancer - a survey. Biochim Biophys Acta. 2007, 1775: 181-232.PubMed
16.
Pinzani P, Salvianti F, Pazzagli M, Orlando C: Circulating nucleic acids in cancer and pregnancy. Methods. 2010, 50: 302-307. 10.1016/j.ymeth.2010.02.004.PubMedCrossRef
17.
Schwarzenbach H, Muller V, Milde-Langosch K, Steinbach B, Pantel K: Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol Biosyst. 2011, 7: 2848-2854. 10.1039/c1mb05197k.PubMedCrossRef
18.
Huang ZH, Li LH, Hua D: Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett. 2006, 243: 64-70. 10.1016/j.canlet.2005.11.027.PubMedCrossRef
19.
Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Burki N, Diesch C, Holzgreve W, Zhong XY: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer. 2009, 8: 105-10.1186/1476-4598-8-105.PubMedPubMedCentralCrossRef
20.
Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013, 368: 1199-1209. 10.1056/NEJMoa1213261.PubMedCrossRef
21.
Alix-Panabieres C, Schwarzenbach H, Pantel K: Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2011, 63: 199-215.PubMedCrossRef
22.
Van der Auwera I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer. 2009, 100: 1277-1286. 10.1038/sj.bjc.6605013.PubMedPubMedCentralCrossRef
23.
Pantel K, Alix-Panabieres C: Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010, 16: 398-406. 10.1016/j.molmed.2010.07.001.PubMedCrossRef
24.
25.
Payne RE, Hava NL, Page K, Blighe K, Ward B, Slade M, Brown J, Guttery DS, Zaidi SA, Stebbing J, Jacob J, Yagüe E, Shaw JA, Coombes RC: The presence of disseminated tumour cells in the bone marrow is inversely related to circulating free DNA in plasma in breast cancer dormancy. Br J Cancer. 2012, 106: 375-382. 10.1038/bjc.2011.537.PubMedCrossRef
26.
Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakagawa T, Martino S, Hoon DS: Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol. 2006, 24: 4270-4276. 10.1200/JCO.2006.05.9493.PubMedCrossRef
27.
Deligezer U, Eralp Y, Akisik EE, Akisik EZ, Saip P, Topuz E, Dalay N: Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Lab Med. 2008, 46: 311-317.PubMedCrossRef
28.
Schwarzenbach H, Muller V, Beeger C, Gottberg M, Stahmann N, Pantel K: A critical evaluation of loss of heterozygosity detected in tumor tissues, blood serum and bone marrow plasma from patients with breast cancer. Breast Cancer Res. 2007, 9: R66-10.1186/bcr1772.PubMedPubMedCentralCrossRef
29.
Schulte-Hermann R, Bursch W, Grasl-Kraupp B, Torok L, Ellinger A, Mullauer L: Role of active cell death (apoptosis) in multi-stage carcinogenesis. Toxicol Lett. 1995, 82-83: 143-148.PubMedCrossRef
30.
Chen X, Bonnefoi H, Diebold-Berger S, Lyautey J, Lederrey C, Faltin-Traub E, Stroun M, Anker P: Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res. 1999, 5: 2297-2303.PubMed
31.
Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, Kasimir-Bauer S: Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res. 2009, 11: R71-10.1186/bcr2404.PubMedPubMedCentralCrossRef
32.
Silva JM, Garcia JM, Dominguez G, Silva J, Miralles C, Cantos B, Coca S, Provencio M, Espana P, Bonilla F: Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann Surg Oncol. 2002, 9: 71-76. 10.1245/aso.2002.9.1.71.PubMedCrossRef
33.
Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, Sanfrutos L, Jareño E, Colas A, España P, Bonilla F: Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival. Clin Cancer Res. 2002, 8: 3761-3766.PubMed
34.
Schwarzenbach H, Eichelser C, Kropidlowski J, Janni W, Rack B, Pantel K: Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression. Clin Cancer Res. 2012, 18: 5719-5730. 10.1158/1078-0432.CCR-12-0142.PubMedCrossRef
35.
Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, O'Shaughnessy J, Kinzler KW, Parmigiani G, Vogelstein B, Diaz LA, Velculescu VE: Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012, 4: 162ra154-10.1126/scitranslmed.3004742.PubMedPubMedCentralCrossRef
36.
Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013, 497: 108-112. 10.1038/nature12065.PubMedCrossRef
37.
Shao ZM, Wu J, Shen ZZ, Nguyen M: p53 mutation in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res. 2001, 7: 2222-2227.PubMed
38.
Page K, Hava N, Ward B, Brown J, Guttery DS, Ruangpratheep C, Blighe K, Sharma A, Walker RA, Coombes RC, Shaw JA: Detection of HER2 amplification in circulating free DNA in patients with breast cancer. Br J Cancer. 2011, 104: 1342-1348. 10.1038/bjc.2011.89.PubMedPubMedCentralCrossRef
39.
Board RE, Wardley AM, Dixon JM, Armstrong AC, Howell S, Renshaw L, Donald E, Greystoke A, Ranson M, Hughes A, Dive C: Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. Breast Cancer Res Treat. 2010, 120: 461-467. 10.1007/s10549-010-0747-9.PubMedCrossRef
40.
Shaw JA, Page K, Blighe K, Hava N, Guttery D, Ward B, Brown J, Ruangpratheep C, Stebbing J, Payne R, Palmieri C, Cleator S, Walker RA, Coombes RC: Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. Genome Res. 2012, 22: 220-231. 10.1101/gr.123497.111.PubMedPubMedCentralCrossRef
41.
Bechmann T, Andersen RF, Pallisgaard N, Madsen JS, Maae E, Jakobsen EH, Bak Jylling AM, Steffensen KD, Jakobsen A: Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer. J Cancer Res Clin Oncol. 2013, 139: 995-1003. 10.1007/s00432-013-1413-5.PubMedCrossRef
42.
Kristensen LS, Hansen LL: PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin Chem. 2009, 55: 1471-1483. 10.1373/clinchem.2008.121962.PubMedCrossRef
43.
Agostini M, Enzo MV, Bedin C, Belardinelli V, Goldin E, Del Bianco P, Maschietto E, D'Angelo E, Izzi L, Saccani A, Zavagno G, Nitti D: Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark. 2012, 11: 89-98.PubMed
44.
Jing F, Zhang J, Tao J, Zhou Y, Jun L, Tang X, Wang Y, Hai H: Hypermethylation of tumor suppressor genes BRCA1, p16 and 14-3-3sigma in serum of sporadic breast cancer patients. Onkologie. 2007, 30: 14-19. 10.1159/000096892.PubMed
45.
46.
Kloten V, Becker B, Winner K, Schrauder MG, Fasching PA, Anzeneder T, Veeck J, Hartmann A, Knuchel R, Dahl E: Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening. Breast Cancer Res. 2013, 15: R4-10.1186/bcr3375.PubMedPubMedCentralCrossRef
47.
Yazici H, Terry MB, Cho YH, Senie RT, Liao Y, Andrulis I, Santella RM: Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2009, 18: 2723-2725. 10.1158/1055-9965.EPI-08-1237.PubMedPubMedCentralCrossRef
48.
Chimonidou M, Tzitzira A, Strati A, Sotiropoulou G, Sfikas C, Malamos N, Georgoulias V, Lianidou E: CST6 promoter methylation in circulating cell-free DNA of breast cancer patients. Clin Biochem. 2013, 46: 235-240. 10.1016/j.clinbiochem.2012.09.015.PubMedCrossRef
49.
Turk V, Bode W: The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991, 285: 213-219. 10.1016/0014-5793(91)80804-C.PubMedCrossRef
50.
Van De Voorde L, Speeckaert R, Van Gestel D, Bracke M, De Neve W, Delanghe J, Speeckaert M: DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat Res. 2012, 751: 304-325. 10.1016/j.mrrev.2012.06.001.PubMedCrossRef
51.
Radpour R, Barekati Z, Kohler C, Lv Q, Burki N, Diesch C, Bitzer J, Zheng H, Schmid S, Zhong XY: Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One. 2011, 6: e16080-10.1371/journal.pone.0016080.PubMedPubMedCentralCrossRef
52.
Yamamoto N, Nakayama T, Kajita M, Miyake T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y, Noguchi S: Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARbeta2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat. 2012, 132: 165-173. 10.1007/s10549-011-1575-2.PubMedCrossRef
53.
Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer. 2006, 94: 1492-1495. 10.1038/sj.bjc.6603117.PubMedPubMedCentralCrossRef
54.
Matuschek C, Bölke E, Lammering G, Gerber PA, Peiper M, Budach W, Taskin H, Prisack HB, Schieren G, Orth K, Bojar H: Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur J Med Res. 2010, 15: 277-286.PubMedPubMedCentral
55.
Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou ES: SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem. 2012, 59: 270-279.PubMedCrossRef
56.
Mirza S, Sharma G, Parshad R, Srivastava A, Gupta SD, Ralhan R: Clinical significance of promoter hypermethylation of ERbeta and RARbeta2 in tumor and serum DNA in Indian breast cancer patients. Ann Surg Oncol. 2012, 19: 3107-3115. 10.1245/s10434-012-2323-5.PubMedCrossRef
57.
Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 2003, 63: 7641-7645.PubMed
58.
Fujita N, Nakayama T, Yamamoto N, Kim SJ, Shimazu K, Shimomura A, Maruyama N, Morimoto K, Tamaki Y, Noguchi S: Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. Oncology. 2012, 83: 273-282. 10.1159/000342083.PubMedCrossRef
59.
Gobel G, Auer D, Gaugg I, Schneitter A, Lesche R, Muller-Holzner E, Marth C, Daxenbichler G: Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat. 2011, 130: 109-117. 10.1007/s10549-010-1335-8.PubMedCrossRef
60.
Liggett TE, Melnikov AA, Marks JR, Levenson VV: Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer. 2011, 128: 492-499. 10.1002/ijc.25363.PubMedCrossRef
61.
Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M: Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. 2005, 65: 1141-1145. 10.1158/0008-5472.CAN-04-2438.PubMedCrossRef
62.
Avraham A, Uhlmann R, Shperber A, Birnbaum M, Sandbank J, Sella A, Sukumar S, Evron E: Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer. 2012, 131: E1166-1172. 10.1002/ijc.27526.PubMedPubMedCentralCrossRef
63.
Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, Raith H, Feldmann K, Kremer AE, Müller S, Geiger S, Hamann GF, Seidel D, Stieber P: Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci. 2008, 1137: 180-189. 10.1196/annals.1448.012.PubMedCrossRef
64.
Roth C, Pantel K, Müller V, Rack B, Janni W, Schwarzenbach H: Apoptos-isrelated deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression. BMC Cancer. 2010, 11: 4-CrossRef
65.
Kuroi K, Tanaka C, Toi M: Clinical significance of plasma nucleosome levels in cancer patients. Int J Oncol. 2001, 19: 143-148.PubMed
66.
Holdenrieder S, Stieber P: Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci. 2009, 46: 1-24. 10.1080/10408360802485875.PubMedCrossRef
67.
Leszinski G, Gezer U, Siegele B, Stoetzer O, Holdenrieder S: Relevance of histone marks H3K9me3 and H4K20me3 in cancer. Anticancer Res. 2012, 32: 2199-2205.PubMed
68.
69.
Cocucci E, Racchetti G, Meldolesi J: Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009, 19: 43-51. 10.1016/j.tcb.2008.11.003.PubMedCrossRef
70.
O'Driscoll L, Kenny E, Mehta JP, Doolan P, Joyce H, Gammell P, Hill A, O'Daly B, O'Gorman D, Clynes M: Feasibility and relevance of global expression profiling of gene transcripts in serum from breast cancer patients using whole genome microarrays and quantitative RT-PCR. Cancer Genomics Proteomics. 2008, 5: 94-104.PubMed
71.
El-Attar NI, Gaefar HA: Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor. Egypt J Immunol. 2007, 14: 111-121.PubMed
72.
García V, García JM, Peña C, Silva J, Domínguez G, Lorenzo Y, Diaz R, Espinosa P, de Sola JG, Cantos B, Bonilla F: Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett. 2008, 263: 312-320. 10.1016/j.canlet.2008.01.008.PubMedCrossRef
73.
Fleischhacker M: Biology of circulating mRNA: still more questions than answers?. Ann N Y Acad Sci. 2006, 1075: 40-49. 10.1196/annals.1368.005.PubMedCrossRef
74.
Kosaka N, Iguchi H, Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010, 101: 2087-2092. 10.1111/j.1349-7006.2010.01650.x.PubMedCrossRef
75.
76.
Cookson VJ, Bentley MA, Hogan BV, Horgan K, Hayward BE, Hazelwood LD, Hughes TA: Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cell Oncol (Dordr). 2012, 35: 301-308. 10.1007/s13402-012-0089-1.CrossRef
77.
Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, Rodriguez-Padilla C, Resendez-Perez D: Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Dis Markers. 2013, 34: 163-169. 10.1155/2013/259454.PubMedPubMedCentralCrossRef
78.
Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL, Law SY, Poon RT, Kwong A: Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One. 2013, 8: e53141-10.1371/journal.pone.0053141.PubMedPubMedCentralCrossRef
79.
Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J: Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 2012, 7: e47003-10.1371/journal.pone.0047003.PubMedPubMedCentralCrossRef
80.
Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A, Burwinkel B: Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer. 2013, 132: 1602-1612. 10.1002/ijc.27799.PubMedCrossRef
81.
Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, Adamietz BR, Wenkel E, Rauh C, Beckmann MW, Fasching PA: Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One. 2012, 7: e29770-10.1371/journal.pone.0029770.PubMedPubMedCentralCrossRef
82.
Zhao FL, Hu GD, Wang XF, Zhang XH, Zhang YK, Yu ZS: Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J Int Med Res. 2012, 40: 859-866. 10.1177/147323001204000304.PubMedCrossRef
83.
Chen W, Cai F, Zhang B, Barekati Z, Zhong XY: The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol. 2012, 34: 455-462.PubMedCrossRef
84.
Ma L, Reinhardt F, Pan E, Soutschek J, Bhat B, Marcusson EG, Teruya-Feldstein J, Bell GW, Weinberg RA: Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat Biotechnol. 2010, 28: 341-347. 10.1038/nbt.1618.PubMedPubMedCentralCrossRef
85.
van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ: Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 2012, 14: R34-10.1186/bcr3127.PubMedPubMedCentralCrossRef
86.
Wang B, Zhang Q: The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. J Cancer Res Clin Oncol. 2012, 138: 1659-1666. 10.1007/s00432-012-1244-9.PubMedCrossRef
87.
Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z, Fan Y, Chen X, Wu C: Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Cell Biochem. 2012, 363: 427-436. 10.1007/s11010-011-1195-5.PubMedCrossRef
88.
Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE, Hoon DS: Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2011, 57: 84-91. 10.1373/clinchem.2010.151845.PubMedCrossRef
89.
Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, Hu C: Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 2013, 139: 223-229. 10.1007/s00432-012-1315-y.PubMedCrossRef
90.
Schwarzenbach H, Milde-Langosch K, Steinbach B, Muller V, Pantel K: Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Res Treat. 2012, 134: 933-941. 10.1007/s10549-012-1988-6.PubMedCrossRef
91.
Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H: Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010, 12: R90-10.1186/bcr2766.PubMedPubMedCentralCrossRef
92.
Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, Cheng JQ: MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008, 28: 6773-6784. 10.1128/MCB.00941-08.PubMedPubMedCentralCrossRef
93.
Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J: Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chin J Cancer Res. 2013, 25: 46-54.PubMedPubMedCentral
94.
Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R, Benner A, Riethdorf S, Trumpp A, Sohn C, Pantel K, Schneeweiss A, Burwinkel B: Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res. 2012, 18: 5972-5982. 10.1158/1078-0432.CCR-12-1407.PubMedCrossRef
95.
Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006, 5: 24-10.1186/1476-4598-5-24.PubMedPubMedCentralCrossRef
96.
Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H: Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One. 2012, 7: e34210-10.1371/journal.pone.0034210.PubMedPubMedCentralCrossRef
97.
Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA: Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012, 118: 2603-2614. 10.1002/cncr.26565.PubMedCrossRef
98.
Ivan M, Harris AL, Martelli F, Kulshreshtha R: Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med. 2008, 12: 1426-1431. 10.1111/j.1582-4934.2008.00398.x.PubMedPubMedCentralCrossRef
99.
DeClerck K, Elble RC: The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy. Front Biosci. 2010, 15: 213-225. 10.2741/3616.CrossRef
100.
Leidner RS, Li L, Thompson CL: Dampening enthusiasm for circulating microRNA in breast cancer. PLoS One. 2013, 8: e57841-10.1371/journal.pone.0057841.PubMedPubMedCentralCrossRef
101.
Locke I, Kote-Jarai Z, Bancroft E, Bullock S, Jugurnauth S, Osin P, Nerurkar A, Izatt L, Pichert G, Gui GP, Eeles RA: Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1399-1402. 10.1158/1055-9965.EPI-05-0971.PubMedCrossRef
102.
Bryzgunova OE, Skvortsova TE, Kolesnikova EV, Starikov AV, Rykova EY, Vlassov VV, Laktionov PP: Isolation and comparative study of cell-free nucleic acids from human urine. Ann N Y Acad Sci. 2006, 1075: 334-340. 10.1196/annals.1368.045.PubMedCrossRef
Metadaten
Titel
Circulating nucleic acids as biomarkers in breast cancer
verfasst von
Heidi Schwarzenbach
Publikationsdatum
01.10.2013
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 5/2013
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3446

Weitere Artikel der Ausgabe 5/2013

Breast Cancer Research 5/2013 Zur Ausgabe

Research article

Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Research article

Quantitative measures of estrogen receptor expression in relation to breast cancer-specific mortality risk among white women and black women

Research article

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk

Letter

Misuse of blood serum to assess exposure to bisphenol A and phthalates

Research article

Pubertal high fat diet: effects on mammary cancer development

Research article

Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise